Motilal Oswal Initiates Coverage on Rubicon Research, Projects 54% Upside in Bull Case

Brokerage Reports

Updated on 31 Oct 2025, 05:28 am

Reviewed By

Aditi Singh | Whalesbook News Team

Short Description :

Brokerage firm Motilal Oswal has initiated coverage on Rubicon Research Limited, a pharmaceutical company focused on regulated markets like the US, with a 'Buy' rating. Motilal Oswal set a price target of ₹740, implying a 22% upside, and projected a bull-case target of ₹930, suggesting a potential 54% surge. The firm highlighted Rubicon's strong R&D, manufacturing capabilities, consistent compliance, and robust business model driven by data-backed product selection.

Motilal Oswal Initiates Coverage on Rubicon Research, Projects 54% Upside in Bull Case

▶

Stocks Mentioned :

Rubicon Research Limited

Detailed Coverage :

Motilal Oswal has launched coverage on Rubicon Research Limited, a fast-growing pharmaceutical manufacturing company specializing in research and development for regulated markets, particularly the United States. The brokerage initiated coverage with a 'Buy' recommendation and a base price target of ₹740 per share, indicating a 22% potential upside from recent closing prices. In a more optimistic scenario, Motilal Oswal's bull-case projection offers a price target of ₹930, which represents a significant 54% potential increase.

Rubicon Research has built a strong market position over the past decade by developing comprehensive capabilities across various dosage forms, excelling in specialty projects, and maintaining manufacturing facilities that adhere to strict US market compliance standards. The company's strategic focus on commercial success and a robust business model, driven by a data-centric approach to product selection and a strong return on investment (ROI) framework, are key factors noted by the brokerage.

Financially, Rubicon Research demonstrated impressive growth, with revenues increasing at a Compound Annual Growth Rate (CAGR) of 60% between FY22 and FY25, reaching ₹1,280 crore. The company transitioned from an operational loss of ₹39.2 crore in FY22 to a positive EBITDA of ₹250 crore with a 19.9% margin in FY25. Similarly, its net loss of ₹67 crore in FY22 turned into a Profit After Tax (PAT) of ₹130 crore in FY25, achieving a Return on Equity (ROE) of 29%.

Looking ahead, Motilal Oswal forecasts continued strong growth from FY25 to FY28, expecting revenue, EBITDA, and PAT to grow at CAGRs of 29%, 32%, and 43% respectively, reaching ₹2,780 crore, ₹580 crore, and ₹390 crore. Given this projected earnings growth and high ROE, the brokerage believes Rubicon Research warrants a premium valuation.

Impact This news could lead to increased investor interest and potentially drive up the stock price of Rubicon Research Limited, especially if the company meets the projected growth targets. The positive outlook from a reputable brokerage firm often influences market sentiment and trading activity for the specific stock. Rating: 8/10.

Difficult Terms and Their Meanings: CAGR: Compound Annual Growth Rate, the average annual growth rate of an investment over a specified period longer than one year. EBITDA: Earnings Before Interest, Taxes, Depreciation, and Amortization, a measure of a company's operating performance. PAT: Profit After Tax, the profit remaining after all expenses and taxes have been deducted. ROE: Return on Equity, a measure of profitability that calculates how much profit a company generates with the money shareholders have invested. Moat: In business, a moat refers to a company's sustainable competitive advantage that protects its long-term profits and market share from competitors.